166 related articles for article (PubMed ID: 28199067)
1. Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.
Stiekema A; Van de Vijver KK; Boot H; Broeks A; Korse CM; van Driel WJ; Kenter GG; Lok CA
Cancer Cytopathol; 2017 Mar; 125(3):197-204. PubMed ID: 28199067
[TBL] [Abstract][Full Text] [Related]
2. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
4. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
[TBL] [Abstract][Full Text] [Related]
5. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.
Jia LT; Zhang YC; Li J; Tian Y; Li JF
Clin Transl Oncol; 2016 Mar; 18(3):233-9. PubMed ID: 26220095
[TBL] [Abstract][Full Text] [Related]
6. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
Drapkin R; von Horsten HH; Lin Y; Mok SC; Crum CP; Welch WR; Hecht JL
Cancer Res; 2005 Mar; 65(6):2162-9. PubMed ID: 15781627
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer and normal fallopian tube high WFDC2 expression does not correlate with HE4 serum level.
Gąsiorowska E; Walkowiak GP; Warchoł W; Lemańska A; Jankowska A; Nowak-Markwitz E
Ginekol Pol; 2015 May; 86(5):335-9. PubMed ID: 26117969
[TBL] [Abstract][Full Text] [Related]
8. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
9. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
10. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
11. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.
Celik B; Bulut T; Yalcin AD
Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997
[TBL] [Abstract][Full Text] [Related]
12. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
13. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
15. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
16. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract][Full Text] [Related]
17. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
18. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.
O'Neal RL; Nam KT; LaFleur BJ; Barlow B; Nozaki K; Lee HJ; Kim WH; Yang HK; Shi C; Maitra A; Montgomery E; Washington MK; El Rifai W; Drapkin RI; Goldenring JR
Hum Pathol; 2013 May; 44(5):734-42. PubMed ID: 23084584
[TBL] [Abstract][Full Text] [Related]
19. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
20. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
Haltia UM; Hallamaa M; Tapper J; Hynninen J; Alfthan H; Kalra B; Ritvos O; Heikinheimo M; Unkila-Kallio L; Perheentupa A; Färkkilä A
Gynecol Oncol; 2017 Jan; 144(1):83-89. PubMed ID: 27871721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
